Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 1;24(7):2485-2491.
doi: 10.31557/APJCP.2023.24.7.2485.

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma

Osama Elbaz  1 , Rana M Shaat  1 , Hasan A Abd El Ghaffar  1 , Sameh Shamaa  2 , Hanaa M Abdel-Masseih  1 , Nahla Anber  3 , Metwaly Ibrahim Mortada  1
Affiliations

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma

Osama Elbaz et al. Asian Pac J Cancer Prev. .

Abstract

Background: Activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic active B-cell receptor signaling and a constitutive activation of the NF-KB pathway. MYD88 L265P mutation occurs as a driving force of NF-KB overactivity in ABC-DLBCL. Nonetheless, in cases of DLBCL, the MYD88 L265P mutation has not yet been investigated in association with the tumour necrosis factor alpha induced protein3 (TNFAIP3) mutation.

Objective: To investigate the frequency of MYD88 and TNFAIP3 mutations in DLBCL and their association to the clinico-hematological profile.

Material and methods: We used real-time polymerase chain reaction in order to search for MYD88 L265P and TNFAIP3 mutations in 100 DLBCL patients.

Results: MYD88 L265P In 20% of cases, the CT heterozygous genotype was discovered. CT heterozygous genotype was more common in ABC type, stage IV, greater IPI groups, extra-nodal infiltration, and BM infiltration. It was also linked to a shorter OS. TNFAIP3 mutation GA heterozygous genotype was detected in 18% of the patients, with ABC-DLBCL subtype accounting for 77.8%. The GA heterozygous genotype was usually related with stage IV, extranodal infiltration, and a reduced life expectancy.

Conclusion: MYD88 L265P and to lesser extent TNFAIP3 mutations are major mutations in ABC- DLBCL and may be predictive factors for poor OS in ABC- DLBCL patients.

Keywords: DLBCL; MYD88; Molecular biology; Real Time PCR; TNFAIP3.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier Survival Curves based on MYD88 L265P (rs387907272) and TNFAIP3 (rs143002189) in DLBCL. (A,B) Overall survival of MYD88 L265P and TNFAIP3 in 100 patients with DLBCL. (C,D) Disease-free survival of MYD88 and TNFAIP3 in 100 DLBCL patients, OS and DFS time is represented in months, myeloid differentiation factor88; TNFAIP3, tumor necrosis factor alpha induced protein3; DLBCL, diffuse large B cell lymphoma
See this image and copyright information in PMC

References

    1. Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study. J Egypt Natl Cancer Inst. 2011;1:17–24. - PubMed
    1. Bu R, Bavi P, Abubaker J, et al. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;10:1971–7. - PubMed
    1. Cao Y, Zhu T, Zhang P, et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget. 2016;50:83294. - PMC - PubMed
    1. Cen H, Tan X, Guo B. A20 mutation is not a prognostic marker for activated B-cell-like diffuse large B-cell lymphoma. PLoS One. 2015;12:e0145037. - PMC - PubMed
    1. Dubois S, Viailly PJ, Mareschal S, et al. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA StudyTargeted NGS Details DLBCL Divergence and Actionable Targets. Clin Cancer Res. 2016;12:2919–28. - PubMed

MeSH terms

Substances